{
    "title": "AstraZeneca wins EU backing for heart drug, but suffers lung cancer setback",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-11553447/AstraZeneca-drug-Imfinzi-fails-monotherapy-type-lung-cancer.html",
    "date": "2022-12-19",
    "keywords": [
        "cancer",
        "drug",
        "heart",
        "failure",
        "lung",
        "imfinzi",
        "forxiga",
        "death",
        "mitra",
        "monday",
        "class",
        "field",
        "trial",
        "risk",
        "astrazeneca",
        "goal",
        "latestage",
        "study",
        "pdl1",
        "johnson",
        "grover",
        "dec",
        "endorsement",
        "dapagliflozin",
        "treatment",
        "company",
        "union",
        "eu",
        "approval",
        "forxigas",
        "population",
        "dobber",
        "business",
        "assumption",
        "indication",
        "whilst",
        "story",
        "patent",
        "exclusivity",
        "analyst",
        "recommendation",
        "analysis",
        "cause",
        "muscle",
        "blood",
        "range",
        "health",
        "form",
        "monotherapy",
        "chemotherapy",
        "cell",
        "subgroup",
        "mortality",
        "statement",
        "year",
        "bodys",
        "body",
        "surface",
        "ability",
        "disease",
        "subset",
        "tumour",
        "expression",
        "setback",
        "deal",
        "tagrisso",
        "amp",
        "therapy",
        "reporting",
        "yadarisa",
        "shabong",
        "bengaluru",
        "editing",
        "rashmi",
        "aich",
        "louise"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}